Introducing the pioneering AbiprotTM technology
We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.
We are focusing on finding new treatment paradigms for severe diseases such as aggressive metastatic cancer and pain. We also work on two type 2 diabetes programs through a collaboration with big pharma.Learn more
Find out more about our portfolio
Oblique Therapeutics currently has eleven programs in the pipeline with a focus on pain and aggressive-metastatic cancer.
Four current programs are being developed in collaboration with leading pharmaceutical companies.Learn More
Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.